2 results
Approved WMOCompleted
primaryTo assess the safety and tolerability of multiple, once-daily oral doses of RDN-929 over 28 days in healthy older adult subjects and early symptomatic AD subjects.secondaryTo assess the plasma and CSF pharmacokinetics (PK) of RDN-929 in…
Approved WMOPending
To determine the safety and tolerability and to establish a preliminary RP2D and/or an MTD or an MAD of MK-4464 administered via IV infusion as monotherapy and in combination with pembrolizumab IV infusion